IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology, Inc. announced today that interim Phase 3 monotherapy data from the BOND-003 study will be presented as a late-breaking abstract at the upcoming 24 th ...
Cross-trial analyses comparing ANKTIVA + BCG with nadofaragene firadenovec-vncg and TAR-200 provide important context, particularly in the absence of head-to-head data, highlighting its efficacy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results